company background image
GLPG

Galapagos ENXTAM:GLPG Stock Report

Last Price

€52.96

Market Cap

€3.5b

7D

0.5%

1Y

3.4%

Updated

17 Aug, 2022

Data

Company Financials +
GLPG fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GLPG Stock Overview

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.

Galapagos Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Galapagos
Historical stock prices
Current Share Price€52.96
52 Week High€66.28
52 Week Low€41.30
Beta0.24
1 Month Change-1.23%
3 Month Change-0.71%
1 Year Change3.36%
3 Year Change-65.45%
5 Year Change-29.88%
Change since IPO231.00%

Recent News & Updates

Shareholder Returns

GLPGNL BiotechsNL Market
7D0.5%2.4%0.2%
1Y3.4%-15.0%-14.8%

Return vs Industry: GLPG exceeded the Dutch Biotechs industry which returned -14.1% over the past year.

Return vs Market: GLPG exceeded the Dutch Market which returned -13.4% over the past year.

Price Volatility

Is GLPG's price volatile compared to industry and market?
GLPG volatility
GLPG Average Weekly Movement4.4%
Biotechs Industry Average Movement8.0%
Market Average Movement4.7%
10% most volatile stocks in NL Market7.9%
10% least volatile stocks in NL Market2.9%

Stable Share Price: GLPG is not significantly more volatile than the rest of Dutch stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GLPG's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19991,344Paul Stoffelshttps://www.glpg.com

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

Galapagos Fundamentals Summary

How do Galapagos's earnings and revenue compare to its market cap?
GLPG fundamental statistics
Market Cap€3.48b
Earnings (TTM)-€80.60m
Revenue (TTM)€505.14m

6.9x

P/S Ratio

-43.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLPG income statement (TTM)
Revenue€505.14m
Cost of Revenue€452.74m
Gross Profit€52.40m
Other Expenses€133.00m
Earnings-€80.60m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 03, 2022

Earnings per share (EPS)-1.23
Gross Margin10.37%
Net Profit Margin-15.96%
Debt/Equity Ratio0%

How did GLPG perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is GLPG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLPG?

Other financial metrics that can be useful for relative valuation.

GLPG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does GLPG's PS Ratio compare to its peers?

GLPG PS Ratio vs Peers
The above table shows the PS ratio for GLPG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average23.6x
PHARM Pharming Group
3.7x12.5%€729.4m
IDIA Idorsia
61.3x52.7%CHF2.7b
603087 Gan & Lee Pharmaceuticals
5.9x16.7%CN¥22.6b
688276 Changchun BCHT Biotechnology
23.5x33.1%CN¥25.6b
GLPG Galapagos
6.9x5.5%€3.5b

Price-To-Sales vs Peers: GLPG is good value based on its Price-To-Sales Ratio (6.9x) compared to the peer average (23.6x).


Price to Earnings Ratio vs Industry

How does GLPG's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Sales vs Industry: GLPG is good value based on its Price-To-Sales Ratio (6.9x) compared to the European Biotechs industry average (16.1x)


Price to Sales Ratio vs Fair Ratio

What is GLPG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLPG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ratio19.6x

Price-To-Sales vs Fair Ratio: GLPG is good value based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (19.6x).


Share Price vs Fair Value

What is the Fair Price of GLPG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLPG (€52.96) is trading above our estimate of fair value (€3.16)

Significantly Below Fair Value: GLPG is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Galapagos forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


1.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLPG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLPG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLPG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GLPG's revenue (5.5% per year) is forecast to grow slower than the Dutch market (7.7% per year).

High Growth Revenue: GLPG's revenue (5.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GLPG is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Galapagos performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-19.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GLPG is currently unprofitable.

Growing Profit Margin: GLPG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GLPG is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.

Accelerating Growth: Unable to compare GLPG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GLPG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).


Return on Equity

High ROE: GLPG has a negative Return on Equity (-3.05%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Galapagos's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GLPG's short term assets (€4.5B) exceed its short term liabilities (€550.7M).

Long Term Liabilities: GLPG's short term assets (€4.5B) exceed its long term liabilities (€1.8B).


Debt to Equity History and Analysis

Debt Level: GLPG is debt free.

Reducing Debt: GLPG has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GLPG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GLPG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 2.6% each year


Discover healthy companies

Dividend

What is Galapagos's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.24%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GLPG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GLPG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GLPG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GLPG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GLPG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Paul Stoffels (60 yo)

0.33yr

Tenure

Dr. Paulus A. Stoffels, also known as Paul, Ph D., M.D., is Chief Executive Officer of Galapagos NV since April 01, 2021 and also serves as its Chairman since April 26, 2022 and also serves as Member of Ma...


Leadership Team

Experienced Management: GLPG's management team is considered experienced (4.9 years average tenure).


Board Members

Experienced Board: GLPG's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Galapagos NV's employee growth, exchange listings and data sources


Key Information

  • Name: Galapagos NV
  • Ticker: GLPG
  • Exchange: ENXTAM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €3.481b
  • Shares outstanding: 65.73m
  • Website: https://www.glpg.com

Number of Employees


Location

  • Galapagos NV
  • Generaal De Wittelaan L11 A3
  • Mechelen
  • Antwerp
  • 2800
  • Belgium

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.